Advancing the cell and gene therapy industry through powerful collaborations

Whether you are working in research, looking to manufacture therapies, or require support in the commercialisation of Advanced Therapy Medicinal Products (ATMPs), we can help.


Cell and Gene Therapy Catapult
Annual Review

Discover More

How we work with you

Benefit from our unique infrastructure and a team of specialists from across the cell and gene therapy life cycle, who can collaborate with you to find solutions to your ATMP challenges.

How we workContact us

Discover our capabilities

We will work with you to accelerate your projects, helping your cell and gene therapies to be safer, more effective, scalable, and affordable. We make it our job to be at the forefront of the latest innovations in cell and gene therapies, so that we are ready to help, whenever you might need us.

ATMP process technologiesEarly-stage developmentManufacturing innovationSkills & trainingFacilitating NHS adoption of ATMPsRegulatory affairsHealth Economics and Market Access (HEMA)
Re Nuron
University of aberdeen
University of oxford

Discover the impact that our work has on the UK cell and gene therapy industry.

It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.


received by ATMP companies in the UK since 2012


increase in cleanroom footprint for manufacturing ATMPs in the UK since 2018


active clinical trials compared to 85 in 2018

7,000+ Jobs

in the sector in the UK compared to 540 in 2012

Our agreement with CGT Catapult is an important strategic step that gives us the flexibility to scale our production capacity, which is crucial to the success of our business both near term, as we prepare for our first clinical trial with QEL-001, and longer term, as we advance our pipeline of novel engineered Treg cell therapies in neuroinflammatory and autoimmune diseases.

Ian McGill - Chief Executive Officer of Quell Therapeutics

Collaboration is important in meeting the needs of this fast-moving sector. We worked closely with four customers in our early adopter program to pilot the new Quantum Flex platform.

Delara Motlagh, General Manager, Cell Therapy Technologies

We are thrilled to be part of this consortium to support the continued innovation of cell therapy manufacturing processes. As a pioneer in the field of personalised cell therapies, we are excited to lend our expertise to this project which we believe can deliver significant benefits for patients.

Edward Samuel, EVP, Technical Operations at Achilles Therapeutics
View all